The decision comes nearly a month after it scrapped a late-stage study of Keytruda in some prostate cancer patients and puts the drugmaker further behind in its quest to develop a treatment for advanced forms of the most common cancer type in the United States.

The company announced its experimental personalized mRNA skin cancer vaccine in combination with Merck & Co Inc.’s drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.

Junshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data.